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Abstract We reported that protein kinase C (PKC) inhibitors
increase the release of arachidonic acid induced by fluoroalumi-
nate (AlF34 ), an unspecific G-protein activator, in intact human
platelets. Now we demonstrate that this effect is independent of
the extracellular Ca2+ concentration and that AlF34 -induced
release of AA is abolished by BAPTA, an intracellular Ca2+
chelator, even in the presence of GF 109203X, a specific and
potent PKC inhibitor. This compound also blocks the liberation
of the secretory phospholipase A2 in the extracellular medium,
indicating that this enzyme is not involved in the potentiation of
arachidonic acid by PKC inhibitors. On the other hand, the latter
effect is completely abolished by treatment of platelets with
AACOCF3, a specific inhibitor of cytosolic phospholipase A2
(cPLA2). These observations indicate that cPLA2 is responsible
for the AlF34 -induced release of arachidonic acid by a mechanism
that is down-regulated by PKC.
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1. Introduction
Agonist-activated platelets produce free fatty acids from the
hydrolysis of membrane phospholipids through the activation
of lipolytic enzymes that are almost inactive in the resting
state. Particular attention has been devoted to the mechanisms
controlling the levels of free arachidonic acid (AA) because it
is the substrate for enzymes leading to the production of
powerful lipid mediators. Nowadays, there is a general con-
sensus that the activation of the Ca2-dependent cytosolic
phospholipase A2 (cPLA2) is required for receptor-mediated
liberation of AA in several cell types including human plate-
lets [1]. The activation of this enzyme requires Ca2-mediated
translocation and phosphorylation [1^3] but, while the re-
quirement of an increase of cytosolic Ca2 concentration is
considered to be essential for the activation of cPLA2, it is still
unclear whether its phosphorylation is strictly required [3]. In
addition, the identity of the kinase(s) involved in receptor-
mediated phosphorylation of cPLA2 in intact cells is not com-
pletely de¢ned.
Previous studies have demonstrated that protein kinase C
(PKC) activators have a synergistic e¡ect on the production
of free AA induced by Ca2 ionophore that is abolished by
PKC inhibitors [4,5].
Our laboratory has recently reported that PKC inhibitors
do not a¡ect the release of AA in thrombin-stimulated human
platelets but, surprisingly, they increase that induced by the
stimulation with £uoroaluminate (AlF34 ), an unspeci¢c and
widely used G-protein activator [6]. This ¢nding suggests
that, in intact human platelets, G-protein-induced liberation
of arachidonic acid may take place by an unknown mecha-
nism that is down-regulated by PKC. Opposite e¡ects were
reported by Akiba et al. [7] with rabbit permeabilized plate-
lets, where the liberation of AA induced by AlF34 was poten-
tiated by phorbol 12-myristate 13-acetate (PMA) and inhib-
ited by staurosporine in the presence of 100 WM external
Ca2. The aim of the present study was the investigation of
the nature of the PLA2 potentiated by PKC inhibitors in
intact human platelets stimulated by AlF34 .
To this end we assessed: (i) the Ca2 dependence of AA
liberation; (ii) the role of the released secretory PLA2
(sPLA2); (iii) the e¡ect of a selective cPLA2 inhibitor.
Our results demonstrate that AlF34 triggers cPLA2 activa-
tion by a mechanism that does not depend on the extracellular
Ca2 concentration and is up-regulated by the inhibition of
PKC.
2. Materials and methods
2.1. Materials
[5,6,8,9,11,12,14,15-3H]Arachidonic acid ([3H]AA; 191^220 Ci/
mmol) was purchased from NEN Research Products (Boston, MA,
USA). [9,10(N)- 3H]Oleic acid was from Amersham Pharmacia Bio-
tech (Essex, UK). Prostacyclin (PGI2), bovine serum albumin (BSA
fraction V) and apyrase were from Sigma Chemical (St. Louis,
MO, USA). Bovine thrombin (Topostasin) was from Roche (Basel,
Switzerland). Fura 2-AM, BAPTA-AM, staurosporine, H-7 (1-(5-iso-
quinolinylsulfonyl)-2-methylpiperazine), AACOCF3 (arachidonyltri-
£uoromethyl ketone), bisindolylmaleimide I (GF-109203X) and bisin-
dolylmaleimide V were purchased from Calbiochem-Novabiochem
Corporation (La Jolla, CA, USA). Silica gel 60A plates (Whatman
International Ltd, Maidstone, UK) were used for thin-layer chroma-
tography.
2.2. Preparation of human platelets
Blood was obtained from healthy volunteers using ACD as anti-
coagulant. Platelets were pelleted in the presence of 0.2 WM PGI2 and
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50 U/ml heparin and then resuspended in Tyrode’s bu¡er containing
0.35% BSA, apyrase (20 Wg/ml) and PGI2 (0.2 WM). This procedure
was repeated twice to obtain washed platelets (WP) which were ¢nally
resuspended, unless di¡erently indicated, in Tyrode’s bu¡er containing
0.35% BSA without addition of Ca2 and Mg2 (standard Tyrode’s
bu¡er) [6].
2.3. Preparation of platelets loaded with Fura 2-AM
WP were resuspended in standard Tyrode’s bu¡er and the volume
was adjusted to give 5U108 cells/ml and then incubated with 4 WM
Fura 2-AM at 37‡C for 45 min [8]. Platelets were then pelleted and
resuspended in Tyrode’s bu¡er (2.5U108 cells/ml). When indicated,
platelets were incubated with Fura 2-AM and 100 WM BAPTA/AM or
with a corresponding volume of its vehicle (DMSO).
2.4. Stimulation of platelets and determination of cytosolic free Ca2+
Fura 2-loaded platelet suspensions (0.5 ml) were placed in a cuvette,
kept at 37‡C under continuous stirring, in the sample holder of a RF-
5000 spectro£uorimeter (Shimatzu Co., Kyoto, Japan) equipped with
software for the calculation of Ca2 concentration, according to
Grynkiewicz et al. [9] using a dissociation constant for Fura 2 of
224 nM. This task was achieved by monitoring the £uorescence ratio
at two excitation wavelengths (336 and 380 nm) with emission set at
510 nm. Rmax was determined by lysing platelets with 0.2% Triton
X-100 in the presence of a saturating Ca2 concentration. Rmin was
determined by addition of 10 mM EGTA. Ca2 concentration in the
standard Tyrode’s bu¡er was determined as above using Fura 2 in-
stead Fura 2-AM.
2.5. Preparation of platelets labelled with [3H]arachidonic acid
Washed labelled platelets (WLP) were prepared as previously re-
ported [6]. Brie£y, resuspended platelets were incubated with [3H]AA
(1 WCi/ml of platelet suspension) at 37‡C for 1 h. Further washes
removed the excess of labelled precursor. Finally, WLP were resus-
pended (2.5U108/ml) in a convenient volume of standard Tyrode’s
bu¡er. When indicated platelets were loaded with BAPTA/AM (100
WM for 45 min at 37‡C) [8].
2.6. Stimulation of WLP and determination of the radioactivity
associated with arachidonic acid
WLP suspensions (0.5 ml) were stimulated with thrombin 0.5 U/ml
for 3 min or with AlF34 (NaF and AlCl3 solution in a 5000:1 molar
ratio) for 20 min under continuous stirring at 1100 rpm. When in-
dicated, WLP were preincubated with PMA (100 nM for 5 min),
staurosporine (200 nM for 4 min), H-7 (200 WM for 4 min), GF
109203X (11 WM for 5 min) or AACOCF3 (20^60 WM for 2 min)
[10] before stimulation with AlF34 or with thrombin. Platelet aggre-
gation was monitored by photometry (Aggrecorder, Menarini, Milan,
Italy). Lipid extraction, AA isolation and determination of radioac-
tivity were performed as previously described [6].
2.7. Assay of platelet sPLA2
Platelet sPLA2 shows a marked preference for substrate presented
as Escherichia coli membranes [11] which contain mainly phosphatid-
ylethanolamine (W70% of total phospholipids). Thus, [3H]oleic acid-
labelled E. coli is generally used as a substrate for assaying non-pan-
creatic sPLA2. This substrate was prepared according to Patriarca et
al. [12] and washed as described by Kramer and Pepinski [13]. The
suitability of this substrate was checked using bee venom PLA2. After
stimulation, platelets (5U108/ml) were pelleted and convenient ali-
quots of supernatants were incubated with autoclaved [3H]oleic
acid-labelled E. coli (approximately 30 nCi/sample). Enzyme assay
was carried out according to Mueller et al. [14] in a total volume of
0.3 ml in the presence of 5 mM CaCl2 and 1 mg/ml BSA.
2.8. Statistical analysis
Data were analyzed by ANOVA followed by multiple comparison
(Sche¡e¤’s test).
Fig. 1. E¡ect of extracellular Ca2 concentration on free cytosolic
Ca2 concentration in stimulated intact human platelets. WP were
loaded with Fura 2-AM and stimulated with AlF34 (21 mM NaF
for 20 min) or thrombin (0.5 U/ml for 3 min). Data are expressed
as nM cytosolic Ca2 and are the mean þ S.D. (n = 7^15).
Table 1
E¡ect of extracellular Ca2 concentration and PKC inhibitors on free cytosolic Ca2 changes and on AA release induced by AlF34 in human
intact platelets
Addition Standard bu¡er+EGTA (0.1 mM) Standard bu¡er Standard bu¡er+Ca2 (1 mM)
[Ca2]stim/[Ca2]rest AA
(nCi/109 platelets)
[Ca2]stim/[Ca2]rest AA
(nCi/109 platelets)
[Ca2]stim/[Ca2]rest AA
(nCi/109 platelets)
None 1 13.9 þ 3.7 1 10.6 þ 3.0 1 13.7 þ 4.7
AlF34 3.9 þ 2.7 47.3 þ 7.4* 4.2 þ 1.1 49.6 þ 13.0* 5.8 þ 2.3 49.3 þ 14.2*
+Staurosporine 3.6 þ 0.6 120.4 þ 36.6** 3.7 þ 0.9 103.3 þ 30.0** 4.2 þ 1.5 121.0 þ 37.5**
+H-7 2.5 þ 0.2 125.3 þ 40.8** 2.6 þ 0.4 125.4 þ 36.4** 4.5 þ 0.1 143.3 þ 41.0**
+GF-109203X 4.5 þ 1.5 128.4 þ 16.0** 3.2 þ 0.5 123.1 þ 25.0** 6.4 þ 2.6 160.4 þ 31.3**
Platelets were treated with staurosporine (200 nM for 4 min), H-7 (200 WM for 4 min) or GF 109203X (11 WM for 5 min) before stimulation
with AlF34 (21 mM for 20 min). Calcium data are expressed as the ratio between Ca
2 concentration measured immediately before stimulation
([Ca2]rest) and the maximal concentration attained after addition of AlF34 ([Ca
2]stim). All data are the mean þ S.D. from at least two experi-
ments in duplicate.
*P6 0.05 versus none.
**P6 0.05 versus AlF34 .
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3. Results
3.1. E¡ect of extracellular Ca2+ concentration on
AlF34 -induced cytosolic free Ca
2+ concentration and
arachidonic acid release
The concentration of cytosolic free Ca2 in unstimulated
human platelets, resuspended in Tyrode’s bu¡er without
Mg2 and Ca2 added (standard Tyrode’s bu¡er), was
68 þ 26 nM (n = 15). The concentration of Ca2 in this bu¡er
was 2 WM.
As shown in Fig. 1, after the stimulation of platelets with
0.5 U/ml thrombin in standard bu¡er, the maximal concen-
tration of cytosolic free Ca2 was 551 þ 172 nM (n = 10) in
accordance with previous reports [15,16]. Under the same
conditions AlF34 (21 mM NaF) increased free Ca
2 to
280 þ 16 nM (n = 15). Preincubation with aspirin (200 WM
for 30 min) did not a¡ect the Ca2 rise induced by AlF34 .
In a nominally Ca2-free medium (0.1 mM EGTA added
2 min before stimulation) Ca2 level in resting platelets was
31.9 þ 11.0 and the addition of AlF34 brought intracellular
Ca2 to 138 þ 37 nM (n = 7). On the other hand, when plate-
lets were exposed to 1 mM Ca2 for 2 min, the stimulation
with AlF34 caused an increase in cytosolic free Ca
2 concen-
tration that reached a value of 602 þ 129 nM (n = 7). These
observations con¢rm previous results [15] indicating that the
increase of cytosolic free Ca2 produced by AlF34 is due to
both Ca2 in£ux and mobilization from intracellular stores.
PKC inhibitors (staurosporine, H-7 or GF-109203X) did
not cause any signi¢cant change in the levels of £uorescence
with respect to control samples up to 25 min after their addi-
tion to the media and they did not signi¢cantly interfere with
the rise of cytosolic Ca2 induced by AlF34 , either in the
absence or in the presence of extracellular Ca2 (Table 1).
Similarly, non-signi¢cant changes were observed after prein-
cubation of platelets with PMA (100 nM for 5 min).
When WLP were stimulated with AlF34 (21 mM NaF)
under identical conditions the production of [3H]AA was ab-
solutely independent of the extracellular Ca2 concentration.
However, staurosporine, H-7 or GF 109203X caused a large
increase in [3H]AA after stimulation with AlF34 which was
also independent of the extracellular Ca2 concentration (Ta-
ble 1), while an analogue of GF 109203X (bisindolylmale-
imide V) inactive on PKC did not a¡ect AlF34 -induced AA
Fig. 2. E¡ect of intracellular Ca2 chelation on arachidonic acid re-
lease. WLP were loaded with BAPTA/AM (100 WM) and then
stimulated with AlF34 (21 mM NaF) for 20 min or thrombin (0.5 U/
ml for 3 min). When indicated WLP were preincubated with GF
109203X (11 WM for 5 min). Data are the mean þ S.D. from two ex-
periments in duplicate. *P6 0.05 versus resting; **P6 0.05 versus
AlF34
Fig. 3. E¡ect of arachidonyltri£uoromethyl ketone on the release of
arachidonic acid induced by AlF34 . WLP were resuspended in Ty-
rode’s bu¡er containing 0.05% BSA, preincubated with AACOCF3
(20^60 WM for 2 min) and/or GF 109203X (11 WM for 5 min) and
stimulated with AlF34 (21 mM NaF) for 20 min. Data are expressed
as radioactivity associated with AA (% of total lipid radioactivity)
and are the mean þ S.D. of two experiments in duplicate. *P6 0.05
versus control.
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release (data not shown). The potentiation of AA release due
to PKC inhibitors was also observed in aspirin-treated plate-
lets (data not shown). In some experiments, platelets were
resuspended in standard Tyrode’s bu¡er, preincubated with
100 WM BAPTA/AM [8] and then loaded with Fura-2. The
stimulation of BAPTA-treated platelets with AlF34 caused a
slight but signi¢cant increase in cytosolic free Ca2 that, how-
ever, always remained below the levels observed in resting
platelets kept in standard bu¡er (data not shown).
The chelation of intracellular Ca2 with BAPTA completely
blocked the release of labelled AA in both thrombin- and
AlF34 -stimulated platelets, even when preincubated with GF
109203X (Fig. 2).
3.2. cPLA2 inhibition and release of arachidonic acid
AACOCF3 (60 WM), a speci¢c cPLA2 inhibitor, blocked the
liberation of AA induced by AlF34 even in the presence of GF
109203X (Fig. 3) and it caused a dose-dependent reduction of
the release of labelled AA in thrombin-stimulated platelets
(Fig. 3, inset). It should be mentioned that AACOCF3 (20^
60 WM) caused a dose-dependent increase in the radioactivity
associated with AA in unstimulated platelets, in agreement
with previous reports [17] (data not shown).
3.3. Release of sPLA2
sPLA2 is released in the extracellular medium following
stimulation of human platelets with PMA, thrombin or
AlF34 . The preincubation with GF 109203X inhibited the re-
lease of the enzyme in the extracellular medium induced by
these agonists (Fig. 4).
4. Discussion
AlF34 is a widely used tool for testing the involvement of
trimeric G-proteins in a given pathway because it binds to GK-
GDP mimicking the Q-phosphate of GTP [18]. The exposure
of intact platelets to AlF34 induces aggregation, release of
granule contents and liberation of AA from membrane phos-
pholipids [19]. The latter event is achieved by a mechanism, as
yet uncharacterized, which is distinct from that utilized by
thrombin. In fact, the treatment of intact human platelets
with neomycin or sodium nitroprusside inhibits the liberation
of AA induced by thrombin but not by AlF34 [19]. On the
other hand, inhibitors of PKC potentiate the release of AA
and do not a¡ect that induced by thrombin [6]. Our hypoth-
esis is that AlF34 triggers a G-protein-mediated mechanism
that leads to the liberation of AA, which is speci¢cally inhib-
ited by one or more phosphorylation reactions catalyzed by
PKC. The identity of the phospholipase activated by AlF34
and regulated by PKC is unknown so far.
Halenda et al. [4] reported that PKC activators potentiate
the release of AA induced by Ca2 ionophores in human
platelets, an e¡ect suppressed by PKC inhibitors. Similar re-
sults were obtained with permeabilized rabbit platelets in the
presence of 1 mM Ca2 or stimulated with GTP-Q-S or AlF34
in the presence of 100 WM Ca2 [7]. These observations are
clearly in contrast with our results obtained with intact plate-
lets stimulated with AlF34 in the presence of 2 WM external
Ca2[6]. However, it should be considered that the treatment
with Ca2 ionophore or the permeabilization of platelets, in
the presence of relatively large Ca2 concentrations, may
cause an increase in cytosolic concentration much larger
than that attainable in intact platelets stimulated under phys-
iological conditions. In this study we have shown that AlF34
stimulation causes an increase in cytosolic Ca2 that varies
depending on the extracellular concentration of the cation
but it never exceeds that induced by thrombin [16]. Further-
more, we have demonstrated that the rise of cytosolic Ca2
concentration induced by AlF34 is not a¡ected by PKC inhib-
itors. This excludes the possibility that the large increase in
AA release provoked by PKC inhibitors and observed during
stimulation of intact platelets with AlF34 is related to an in-
£uence on the cytosolic Ca2 concentration.
We have also demonstrated that AlF34 induces the release in
the extracellular medium of sPLA2, a ¢nding not previously
reported, showing that the release of this enzyme is a G-pro-
tein-mediated process. PKC inhibitors abolished the release of
sPLA2, thus a contribution of this enzyme to the release of
AA induced by AlF34 can be excluded. This conclusion is
further supported by the observation that the potentiation
of the AlF34 -induced release of AA by PKC inhibitors is
also observed with EGTA in the medium, since sPLA2 re-
quires millimolar concentrations of Ca2 for optimal activity
[14].
The observation that the liberation of AA induced by AlF34
is strictly Ca2-dependent and takes place with submicromo-
lar concentrations of cytosolic Ca2 suggests that its potentia-
tion by PKC inhibitors is somehow related to the activation of
cPLA2. This assumption is further supported by the observa-
Fig. 4. E¡ect of PKC inhibition on the release of sPLA2. WP were
resuspended in Tyrode’s bu¡er and, after preincubation with GF
109203X (11 WM for 5 min), were stimulated with AlF34 (21 mM
NaF for 20 min) or Thrombin (0.5 U/ml for 3 min) or PMA
(100 nM for 5 min). After stimulation platelets were pelleted and
sPLA2 activity was assayed in the supernatants and in platelet ly-
sates. Data (mean þ S.D.) are from two experiments in duplicate
and are expressed as a fraction of activity released with respect to
total. *P6 0.05 versus control.
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tion that a selective inhibitor of this enzyme suppresses the
AlF34 -induced release of AA and the e¡ect of PKC inhibitors.
cPLA2 has various sites for potential phosphorylation by
serine/threonine and tyrosine kinases and consensus sequences
for mitogen-activated protein kinase (MAPK) as well for
PKC and PKA [20]. However, the nature of the protein kin-
ase(s) involved in the phosphorylation of platelet cPLA2, in-
duced by physiological agonists or non-physiological com-
pounds, is still unclear. Particularly, collagen and thrombin
activate cPLA2 by a PKC-independent mechanism [21] and
p38mapk appears to be involved in this process [22,23]. On
the other hand, PKC-mediated phosphorylation of cPLA2
by p42/p44mapk takes place in platelets treated with phorbol
esters and Ca2 ionophore [24].
These observations and our results suggest that, in AlF34 -
stimulated platelets, PKC has to exert a down-regulation of
the liberation of AA upstream of the phosphorylation and
activation of cPLA2. The site of this e¡ect is still unknown
but it is reasonable to suppose that it does not belong either
to the pathways activated by collagen or thrombin, since
those are not or little a¡ected by speci¢c PKC inhibitors
[6,22], or to that triggered by phorbol esters and Ca2 because
it is blocked by PKC inhibitors.
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